Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...
Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, despite a phase 2 trial missing its main efficacy measure. In the 18-month ...
Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to ...
It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...
Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...
Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...
Parallel reviews of new medicines by the UK's MHRA drug regulator and reimbursement authority NICE benefit industry more than patients and the NHS. That is the contention voiced by Huseyin Naci at the ...
Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision comes ...
In November 2025, the UK government introduced the national "Government Strategy and Roadmap" for phasing out animal testing.[1] The US Food and Drug Administration (FDA) has also issued a roadmap and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results